AstraZeneca plc (LON:AZN) Stock Rating Reaffirmed by Citigroup Inc.
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by investment analysts at Citigroup Inc. in a research note issued to investors on Wednesday.
Several other research analysts have also recently issued reports on the company. Deutsche Bank AG decreased their price target on AstraZeneca plc from GBX 5,500 ($71.24) to GBX 5,350 ($69.30) and set a “buy” rating for the company in a research note on Friday, April 28th. Barclays PLC reissued an “overweight” rating and issued a GBX 6,000 ($77.72) price target on shares of AstraZeneca plc in a research note on Monday, March 27th. Societe Generale reissued a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, March 23rd. HSBC Holdings plc cut AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($58.29) price target for the company. in a research note on Friday, April 7th. Finally, Jefferies Group LLC cut AstraZeneca plc from a “buy” rating to a “hold” rating and decreased their price target for the stock from GBX 5,350 ($69.30) to GBX 5,050 ($65.41) in a research note on Monday, April 10th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of GBX 5,267.68 ($68.23).
Shares of AstraZeneca plc (LON AZN) traded up 0.49% during trading on Wednesday, hitting GBX 5130.00. 1,358,219 shares of the stock were exchanged. The stock’s market cap is GBX 64.95 billion. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The stock’s 50 day moving average price is GBX 5,259.89 and its 200 day moving average price is GBX 4,769.91.
TRADEMARK VIOLATION WARNING: “AstraZeneca plc (LON:AZN) Stock Rating Reaffirmed by Citigroup Inc.” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/07/09/astrazeneca-plc-lonazn-stock-rating-reaffirmed-by-citigroup-inc.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.